Table 1 The baseline characteristics of patients in the two groups.
Baseline characteristics | POS-Tab (n = 46) | POS-OS (n = 98) | Total (n = 144) | P value |
|---|---|---|---|---|
Population characteristics | ||||
Age(years)/M (P25, P75) | 55.0(17.0,67.0) | 37.5(13.0,53.5) | 39.0(14.5,58.0) | 0.003 |
Male/case (%) | 31(67.4%) | 54(55.1%) | 85(59.0%) | 0.162 |
Concomitant disease/case (%) | ||||
Leukemia | 9(19.6%) | 61(62.2%) | 70(51.4%) | < 0.001 |
Lymphadenoma | 1(2.2%) | 4(4.1%) | 5(3.5%) | 0.924 |
Myelodysplastic syndrome | / | 3(3.1%) | 3(2.1%) | 0.551 |
Solid tumor | 6(13%) | 3(3.1%) | 9(6.2%) | 0.053 |
Transplant status | 18(39.1%) | 58(59.2%) | 76(52.8%) | 0.025 |
Diabetes mellitus | 15(32.6%) | 14(14.3%) | 29(20.1%) | 0.011 |
GVHD(graft versus host disease) | 9(19.6%) | 34(34.7%) | 43(29.9%) | 0.064 |
Concomitant status/case (%) | ||||
Renal replacement therapy | 6(13.0%) | 3(3.1%) | 9(6.2%) | 0.053 |
Mechanical ventilation | 10(21.7%) | 4(4.1%) | 14(9.7%) | 0.002 |
Hypoalbuminemia (< 30 g/L) | 6(13.0%) | 12(12.2%) | 18(12.5%) | 0.893 |
Neutropenia(< 1.5 × 109/L) | 7(15.2%) | 64(65.3%) | 71(49.3%) | < 0.001 |
Infection site/case (%) | ||||
Pulmonary infection | 45(97.8%) | 85(86.7%) | 130(90.3%) | 0.073 |
Bloodstream infection | 8(17.4%) | 24(24.5%) | 32(22.2%) | 0.339 |
Abdominal infection | 1(2.2%) | 3(3.1%) | 4(2.8%) | > 0.999 |
Urinary infection | 2(4.3%) | 2(2%) | 4(2.8%) | 0.809 |
Culture of the pathogen/case (%) | ||||
Aspergillus | 30(65.2%) | 63(64.3%) | 93(64.6%) | 0.913 |
Mucor | 5(10.9%) | 10(10.2%) | 15(10.4%) | > 0.999 |
Combined antifungals/case (%) | ||||
Caspofungin | 11(23.9%) | 16(16.3%) | 27(18.8%) | 0.277 |
Micafungin | / | 6(6.1%) | 6(4.2%) | 0.205 |
Amphotericin B Liposome | 5(10.9%) | 3(3.1%) | 8(5.6%) | 0.129 |
Amphotericin B Cholesteryl Sulfate | / | 4(4.1%) | 4(2.8%) | 0.398 |
Flucytosine | 3(6.5%) | 1(1%) | 4(2.8%) | 0.184 |
Combined immunosuppressant | ||||
Methylprednisolone | 17(37.0%) | 31(31.6%) | 48(33.3%) | 0.527 |
Prednisone | 6(13.0%) | 8(8.2%) | 14(9.7%) | 0.535 |
Cyclosporin | 4(8.7%) | 47(48%) | 51(35.4%) | < 0.001 |
Tacrolimus | 4(8.7%) | 6(6.1%) | 10(6.9%) | 0.830 |
Lucotinib | 3(6.5%) | 10(10.2%) | 13(9.0%) | 0.684 |
Methotrexate | 2(4.3%) | 27(27.6%) | 29(20.1%) | 0.001 |
Rituximab | 1(2.2%) | 11(11.2%) | 12(8.3%) | 0.131 |
Therapeutic regimen | ||||
Posaconazole duration (Days)/M(P25, P75) | 7.5(4.2,11.5) | 10.0(5.2,16.0) | 9.0(5.0,15.0) | 0.073 |
Mean hospital stay (Days)/M(P25, P75) | 16.0(7.0,28.0) | 26.0(11.0,36.0) | 22.5(9.0,33.0) | 0.027 |
Posaconazole daily dose (mg)/M(P25, P75) | 300.0(200.0,300.0) | 600.0(541.9,800.0) | 591.7(300.0,638.1) | < 0.001 |
Number of therapeutic drugs monitored patients | 8(17.4%) | 12(12.2%) | 20(13.9%) | 0.405 |
